#ASH22: Re­gen­eron claims it has set a 'new bench­mark' in fol­lic­u­lar lym­phoma

NEW OR­LEANS — Re­gen­eron gave re­searchers a first look at in­ter­im re­sults from its Phase II study of a CD20xCD3 bis­pe­cif­ic an­ti­body in pa­tients with re­lapsed/re­frac­to­ry fol­lic­u­lar lym­phoma, with a planned reg­u­la­to­ry fil­ing on tap for next year as it seeks to catch up with ri­val Roche.

Tri­al in­ves­ti­ga­tors said 81.8% of 121 pa­tients with the dis­ease re­spond­ed to Re­gen­eron’s drug odronex­tam­ab, and that 75.2% had a com­plete re­sponse as of the Sept. 15 da­ta cut­off. Me­di­an du­ra­tion of re­sponse and me­di­an du­ra­tion of com­plete re­sponse were both 20.5 months, with me­di­an pro­gres­sion-free sur­vival of 20.2 months, ac­cord­ing to a Mon­day af­ter­noon pre­sen­ta­tion at the an­nu­al Amer­i­can So­ci­ety of Hema­tol­ogy con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER